FDA Authorizes COVID-19 Vaccine Booster for Older Adults, HCWs and Others at High Risk for COVID-19

By Marie Rosenthal

Originally published by our sister publication, Infectious Disease Special Edition

The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 messenger RNA (mRNA) vaccine to enable a booster dose to be administered at least six months after completion of the primary series in people:

• 65 years of age and older;
• 18 through 64 years of age at high risk for severe COVID-19; and
• 18 through 64 years of age whose frequent institutional or occupational exposure